A Fundamental Shift in Cancer Care
At Aulos, we’re on a journey to revolutionize cancer patient care through the development of pioneering IL-2 therapeutics that we believe will transform the treatment of solid tumor cancers. We’re taking on the toughest challenges that have limited the effectiveness of IL-2 therapies: the ability to shift IL-2 activity toward immune activation and away from immune suppression, and preventing the toxic side effects of interleukin-2, including vascular leak syndrome and pulmonary edema.
Abstracts and Publications
FEATURE
A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results from dose escalation (NCT05267626)
Latest News
Aulos stands apart through our new approach to long-standing obstacles in immunotherapy.
AU-007: An Investigational Product Candidate
AU-007 achieves what we believe no other IL-2 therapeutic in development does: tip the balance toward immune activation and prevent binding to vasculature and pulmonary endothelium.
